作者
Jackson T Wright, Sonja Harris-Haywood, Sara Pressel, Joshua Barzilay, Charles Baimbridge, Charles J Bareis, Jan N Basile, Henry R Black, Richard Dart, Alok K Gupta, Bruce P Hamilton, Paula T Einhorn, L Julian Haywood, Syed ZA Jafri, Gail T Louis, Paul K Whelton, Cranford L Scott, Debra L Simmons, Carol Stanford, Barry R Davis
发表日期
2008/1/28
期刊
Archives of Internal Medicine
卷号
168
期号
2
页码范围
207-217
出版商
American Medical Association
简介
Background
Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcomes by race in hypertensive individuals with and without MetS treated with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), an α-blocker (doxazosin mesylate), or an angiotensin-converting enzyme inhibitor (lisinopril).
Methods
A subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind hypertension treatment trial of 42 418 participants. We defined MetS as hypertension plus at least 2 of the following: fasting serum glucose level of at least 100 mg/dL, body mass index (calculated as weight in kilograms divided by height in meters squared) of at least 30, fasting triglyceride levels of at least 150 mg …
引用总数
学术搜索中的文章
JT Wright, S Harris-Haywood, S Pressel, J Barzilay… - Archives of Internal Medicine, 2008